NCT05349760View on ClinicalTrials.gov

A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

March 31, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

June 30, 2025

Conditions

IPF

Interventions

BIOLOGICAL

AMB-05X

A fully human monoclonal immunoglobulin (IgG2) directed against c-fms

DRUG

Placebo

Saline/D5W

Sponsors

Lead Sponsor

AmMax Bio, Inc.

All Listed Sponsors

lead

AmMax Bio, Inc.

INDUSTRY

NCT05349760 - A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter